// App-Quantinova.ai

8020 : Oral ixazomib-dexamethasone versus oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma (MM) patients: A global, multicenter, randomized, open-label, phase 2 trial.

Researchers

Presenter

  • Meletios A. Dimopoulos

Principal Investigators

  • Vadim Doronin

  • Olga Vinogradova

  • HANG QUACH

  • Xavier Leleu

  • Gonzalez montes Yolanda

  • Karthik Ramasamy

  • Alessandra Pompa

  • Mark-David Levin

  • Cindy Lee

  • Ulf-Henrik Mellqvist

  • Roland Fenk

  • Hamdi Sati

  • Alexander Vorog

  • Richard J. Labotka

  • Jichang Du

  • Mohamed Darif

  • Shaji Kumar

Medical Centers

  • Therapeutic Clinic,General Hospital of Athens Alexandra,Athens,Greece

  • Oslo Myeloma Center, Oslo University Hospital, Oslo Norway

  • KG Jebsen Center for B cell malignancies, University of Oslo, Oslo, Norway

  • Central Clinical Hospital, Moscow, Russian Federation

  • City Clinical Hospital n.a. S.P.Botkin, Moscow, Russian Federation

  • St Vincents Hospital University of Melbourne, Fitzroy, VIC, Australia

  • Department of Hematology, CHU la Miletrie and Inserm CIC 1402, Poitiers, France

  • ICO, Girona, Spain

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • Division of Hematology & Stem Cell Transplantation, Fondazione Ca'Granda IRCCS Ospedale Maggiore Policlinico, Milan, Italy

  • Albert Schweitzer Hospital, Dordrecht, Netherlands

  • Department of Rheumatology, The Queen Elizabeth Hospital, SA, Australia

  • Boras Hospital, Boras, Sweden

  • University Hospital Duesseldorf, Dept. of Hematology, Oncology and clinical Immunology, Duesseldorf, Germany

  • Department of Haematology, Singleton Hospital, Swansea Bay University Health Board, Swansea, United Kingdom

  • Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Deerfield, IL

  • Millennium The Takeda Onc Co, Cambridge, MA

  • Mayo Clinic, Rochester, MN

Locations

  • Greece

  • Norway

  • Russia

  • Australia

  • France

  • Spain

  • United Kingdom

  • Italy

  • Netherlands

  • Sweden

  • Germany

  • United States

Companies

  • Millennium Pharmaceu

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Lenalidomide

  • Ixazomib

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multinational

  • Multicenteric

Phase

  • II

Study Id's

  • NCT03170882

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved